Hamps Bio IPO Overview

Hamps Bio IPO is a fixed price issue of Rs 6.22 crores. The issue is entirely a fresh issue of 12.20 lakh shares.

Hamps Bio IPO bidding opened for subscription on December 13, 2024 and will close on December 17, 2024. The allotment for the Hamps Bio IPO is expected to be finalized on Wednesday, December 18, 2024. Hamps Bio IPO will list on BSE SME with tentative listing date fixed as Friday, December 20, 2024.

Hamps Bio IPO price is ₹51 per share. The minimum lot size for an application is 2000. The minimum amount of investment required by retail investors is ₹1,02,000. The minimum lot size investment for HNI is 2 lots (4,000 shares) amounting to ₹2,04,000.

Marwadi Chandarana Intermediaries Brokers Pvt. Ltd. is the book running  lead manager of the Hamps Bio IPO, while Bigshare Services Pvt Ltd is the registrar for the issue.The market maker for Hamps Bio IPO is Pure Broking Private Limited.

Refer to Hamps Bio IPO RHP for detailed information.

Hamps Bio IPO Important dates

Hamps Bio IPO IPO opens on December 13, 2024, and closes on December 17, 2024.

IPO Open Date Friday, December 13, 2024
IPO Close Date Tuesday, December 17, 2024
Basis of Allotment Wednesday, December 18, 2024
Initiation of Refunds Thursday, December 19, 2024
Credit of Shares to Demat Thursday, December 19, 2024
Listing Date Friday, December 20, 2024
Cut-off time for UPI mandate confirmation 5 PM on December 17, 2024

Hamps Bio IPO Financial Performance

Hamps Bio Limited’s revenue increased by 16.41% and profit after tax (PAT) rose by 39.47% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended 31 Oct 2024 31 Mar 2024 31 Mar 2023 31 Mar 2022
Assets 644.00 514.77 395.87 364.31
Revenue 436.42 650.13 558.49 534.46
Profit After Tax 34.08 50.07 35.90 12.15
Net Worth 370.78 337.42 136.30 100.57
Reserves and Surplus 57.18 141.42 -13.70 -49.43
Total Borrowing 138.31 104.52 173.77 204.31

Hamps Bio IPO Key Performance Indicator

The market capitalization of Hamps Bio IPO is Rs 22.22 Cr.

KPI as of Sun, Mar 31, 2024.

KPI Values
ROE 21.14%
ROCE 18.31%
Debt/Equity 0.31
RoNW 14.84%
PAT Margin 7.73
Price to Book Value 2.96
Pre IPO Post IPO
EPS (Rs) 1.60 1.34
P/E (x) 31.94 38.03

Note:

  • The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2024 that is available in RHP.
  • The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of October 31, 2024 that is available in RHP.

Hamps Bio IPO Objectives

The Company intends to use its proceeds as follows:

  1. Purchase of plant & machinery for FMCG division
  2. Enhancing the visibility and awareness of the brand
  3. General corporate purposes

Hamps Bio IPO Lot Size

Investors can bid for a minimum of 2000 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.

Application Lots Shares Amount
Retail (Min) 1 2000 ₹1,02,000
Retail (Max) 1 2000 ₹1,02,000
HNI (Min) 2 4,000 ₹2,04,000

Hamps Bio IPO Details

IPO Date December 13, 2024 to December 17, 2024
Listing Date [.]
Face Value ₹10 per share
Price ₹51 per share
Lot Size 2,000 Shares
Total Issue Size 12,20,000 shares
(aggregating up to ₹6.22 Cr)
Fresh Issue 12,20,000 shares
(aggregating up to ₹ 6.22 Cr)
Issue Type Fixed Price Issue IPO
Listing At BSESME
Share Holding Pre Issue 31,36,000 shares
Share Holding Post Issue 43,56,000 shares
Market Maker Portion 62,000shares

Hamps Bio IPO Company Overview and Services

Incorporated in 2007, Hamps Bio Limited is engaged in the marketing and distribution of pharmaceutical products like tablets, syrups, capsules, injectables, oil, and nutritional supplements.

The company distributes its products through a network of over 50 distributors and e-commerce platforms, including Amazon (US, Canada, EU), Flipkart, and Jio Mart. Their pharma products are sold in 8 states and union territories, while Freeze-dried and Frozen products reach 6 countries and 22 states and union territories.

The company’s business is divided into two segments:

  1. Pharmaceuticals: The company’s pharmaceutical products are marketed under the “Hamps” brand. The range includes tablets, syrups, capsules, injectables, and powders.
  2. Freeze-dried and Frozen products: The FMCG division focuses on freeze-dried and frozen items under the “FzyEzy” brand. The company operates through both B2B and B2C models, offering products under its brand and through contract manufacturing. Freeze-dried and frozen products include Strawberry, Jamun, Mango, Beet Powder, Chikoo powder etc.

The company offers over 180 products across both segments. As of October 31, 2024, The company had 78 employees.

Competitive Strengths:

  • Expert Leadership and Industry Experience Driving Strategic Business Growth
  • Distribution Network with an Expansive E-Retailing Presence
  • Wide and diversified range of products
  • Diversified, global customer base with long-standing relationships
  • Wide Geographical Presence
  • Brand Identity

Hamps Bio IPO SWOT Analysis

Strengths:

  • Diversified Product Portfolio: Hamps Bio operates in two segments: pharmaceuticals (tablets, syrups, capsules, injectables, etc.) and freeze-dried/frozen FMCG products (“FzyEzy” brand). This diversification can mitigate risks associated with relying on a single product category.
  • Established Distribution Network: The company utilizes a network of over 50 distributors and also sells through e-commerce platforms like Amazon, Flipkart, and Jio Mart. This multi-channel distribution strategy increases market reach.
  • Growing Revenue and Profitability: Reports indicate a healthy growth in revenue and a significant increase in profit after tax (PAT) in recent financial years. This suggests positive financial performance.
  • Focus on Both B2B and B2C: The company operates in both business-to-business and business-to-consumer segments, further expanding their potential customer base.

Weaknesses:

  • Relatively Small Scale: As an SME, Hamps Bio’s scale of operations is smaller compared to larger pharmaceutical and FMCG companies. This can limit their ability to compete on price and marketing reach.
  • Dependence on Distributors and E-commerce Platforms: While a diversified distribution network is a strength, dependence on third-party distributors and e-commerce platforms can create vulnerabilities if these relationships are disrupted or if platform policies change.
  • Limited Brand Recognition: Compared to established players in the pharmaceutical and FMCG sectors, Hamps Bio has relatively lower brand recognition. This can make it challenging to attract and retain customers.

Opportunities:

  • Growing Pharmaceutical and FMCG Markets in India: Both the pharmaceutical and FMCG sectors in India are experiencing growth, driven by factors like increasing disposable incomes and health awareness. This provides a favorable market environment for Hamps Bio.
  • Expansion into New Geographies: The company can expand its distribution network and market presence to new regions within India and potentially internationally.
  • Focus on Niche Products: Developing and marketing specialized pharmaceutical or FMCG products could help Hamps Bio differentiate itself from competitors.
  • Strategic Partnerships and Acquisitions: Forming partnerships or acquiring smaller companies could help Hamps Bio expand its product portfolio, distribution network, and market share.

Threats:

  • Intense Competition: The pharmaceutical and FMCG industries are highly competitive, with the presence of both established domestic and international players.
  • Regulatory Changes: Changes in government regulations related to pharmaceuticals, food safety, or e-commerce can impact the company’s operations and profitability.
  • Fluctuations in Raw Material Prices: The cost of raw materials used in pharmaceutical and FMCG products can fluctuate, affecting the company’s margins.
  • Economic Downturn: A slowdown in the Indian economy can negatively impact consumer spending and demand for both pharmaceutical and FMCG products.

Hamps Bio IPO GMP Details

Hamps Bio SME IPO last GMP is ₹40, last updated Dec 16th 2024 12:54 PM. With the price band of 51.00, Hamps Bio SME IPO’s estimated listing price is ₹91 (cap price + today’s GMP).The expected percentage gain/loss per share is 78.43%.>> Hamps Bio SME IPO Retail Subject to Sauda: ₹60800

We update GMP on a daily basis and based on last 7 sessions grey market activities, today IPO GMP points upward and expects a strong listing. The lowest GMP is ₹0, while the highest GMP is ₹40. Stay with us to know the daily price trend of Hamps Bio SME IPO GMP with expected listing price.

GMP Date IPO Price GMP Sub2 Sauda Rate Estimated Listing Price Last Updated
16-12-2024 51.00 ₹40  60800 ₹91 (78.43%) 16-Dec-2024 12:54
15-12-2024 51.00 ₹40  60800 ₹91 (78.43%) 15-Dec-2024 17:26
14-12-2024 51.00 ₹40   60800 ₹91 (78.43%) 14-Dec-2024 22:30
13-12-2024 Open 51.00 ₹35   53200 ₹86 (68.63%) 13-Dec-2024 22:25
12-12-2024 51.00 ₹21  31900 ₹72 (41.18%) 12-Dec-2024 22:29
11-12-2024 51.00 ₹21   31900 ₹72 (41.18%) 11-Dec-2024 22:31
10-12-2024 51.00 ₹0  — ₹ (0%) 10-Dec-2024 18:32

What is IPO GMP?

The grey market premium (GMP) reflects the unofficial trading price of an IPO before its listing, offering insights into its potential market performance. A positive GMP indicates that the IPO may yield profits, while a negative GMP suggests a possible discount upon listing. However, it’s essential to recognize that IPO GMP can be highly volatile. Therefore, investors should not make decisions solely based on the GMP but should thoroughly assess all relevant factors before investing.

Hamps Bio IPO Subscription Status 

Hamps Bio IPO subscribed 144.36 times. The public issue subscribed 255.65 times in the retail category, [.] times in QIB, and 33 times in the NII category by December 16, 2024 3:00:12 PM (Day 2).

Investor Category Subscription (times) Shares Offered* Shares bid for Total Amount (Rs Cr.)* Total Application
Market Maker 1 62,000 62,000 0.32 –
Non-Institutional Buyers*** 33 5,79,000 1,91,06,000 97.44 3,280
Retail Investors 255.65 5,79,000 14,80,22,000 754.91 74,011
Total ** 144.36 11,58,001 16,71,72,000 852.58 1,29,570
Date NII* Retail Total
Day 1
Dec 13, 2024		 2.35 18.87 10.61
Day 2
Dec 16, 2024		 33 255.65 144.36

Hamps Bio IPO Allotment status 

Hamps Bio IPO allotment is expected on Wednesday, December 18, 2024.

Hamps Bio IPO allotment status is not available at this time. Hamps Bio IPO – The allotment status will be available once the basis of allotment is finalized. Please revisit us to check the latest updates for Hamps Bio Limited IPO allotment status.

To check Hamps Bio IPO allotment status, follow the steps below:

  1. Click on the below allotment status check button.
  2. Select Company Name.
  3. Enter your PAN Number, Application Number or DP Client ID (Anyone).
  4. Click on Search.

On securing the allotment, you will receive the credit of equivalent shares in your Demat account.

If you have any concerns or queries about the allotment status, contact Bigshare Services Pvt Ltd either by phone or email. Investors can call on +91-22-6263 8200 or send an email with all relevant details to investor@bigshareonline.com.

Hamps Bio IPO Contact Details

Hamps Bio Limited
2900/112,
GIDC, Near Atul Limited,
Ankleshwar, Bharuch 393 002
Phone: +91 8000006663
Email: info@hampsbio.com
Website: http://www.hampsbio.com/

Disclaimer: Investing in Initial Public Offerings (IPOs) involves substantial risk, and financial returns are not guaranteed. The information provided should not be construed as financial or investment advice. Prospective investors are advised to consider their financial situation, investment objectives, and risk tolerance before participating in an IPO. It is recommended to consult with a qualified financial advisor or professional before making any investment decisions. Past performance is not indicative of future results. Investments in IPOs may be subject to market risk, including the potential loss of principal.

Want to Raise money for your company through SME IPO? Read More